Tissue-type plasminogen activator should not be used in acute ischemic stroke

Archives of Neurology

Volumn 53, Issue 12, 1996, Pages 1306-1308

  Riggs, Jack E ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DOUBLE BLIND PROCEDURE; HAZARD; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 0030461624     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550120118026     Document Type: Short Survey

References (6)

1. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator tor acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy ot the live-year survival in lung cancer. N Engl J Med. 1978;299:1397-1401.
4. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982;306:1259-1262.
5. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981; 211:453-458.
6. del Zoppo GJ. Acute stroke: on the threshold of a therapy? N Engl J Med. 1995;333:1632-1633.